Overview

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that in patients with type 2 diabetes, the addition of exenatide will result in lower time-averaged serum glucose during a 24-hour period, compared with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Eli Lilly and Company
Treatments:
Exenatide